Hydrocortisone Panpharma: Uses, Dosage & Side Effects
An injectable corticosteroid for the emergency treatment of adrenal crisis, severe allergic reactions, and acute inflammatory conditions
Hydrocortisone Panpharma is an injectable corticosteroid containing hydrocortisone sodium succinate, a water-soluble ester of hydrocortisone (cortisol). It is used in situations requiring rapid systemic glucocorticoid therapy, including acute adrenal insufficiency (adrenal crisis), severe allergic reactions and anaphylaxis, status asthmaticus, shock unresponsive to conventional therapy, and various acute inflammatory conditions. As a synthetic form of the body's own cortisol, hydrocortisone provides both glucocorticoid and mineralocorticoid effects. It is listed on the WHO Model List of Essential Medicines and is considered a cornerstone of emergency endocrine and immunological care worldwide.
Quick Facts: Hydrocortisone Panpharma
Key Takeaways
- Hydrocortisone Panpharma is an injectable form of cortisol (the body's primary stress hormone) used in medical emergencies such as adrenal crisis, severe anaphylaxis, and acute asthma exacerbations where rapid systemic corticosteroid action is essential.
- The 100 mg powder for injection is reconstituted with the provided solvent and can be administered intravenously (IV bolus or infusion) or intramuscularly (IM), with IV being preferred in emergency situations for the fastest onset of action.
- Hydrocortisone is listed on the WHO Model List of Essential Medicines and is the corticosteroid of choice for adrenal replacement therapy because it most closely mimics the body's natural cortisol production.
- Short-term emergency use is generally well tolerated, but prolonged or repeated use can lead to adrenal suppression, hyperglycemia, immunosuppression, and osteoporosis; treatment should be tapered gradually rather than stopped abruptly.
- Patients with known adrenal insufficiency should carry an emergency hydrocortisone injection kit and a steroid alert card, and they should be trained in self-injection techniques for use during adrenal crisis when oral medication cannot be taken.
What Is Hydrocortisone Panpharma and What Is It Used For?
Hydrocortisone Panpharma contains the active substance hydrocortisone in the form of hydrocortisone sodium succinate, a water-soluble ester that allows for rapid dissolution and injectable administration. Hydrocortisone is a synthetic form of cortisol, the principal glucocorticoid hormone produced by the zona fasciculata of the adrenal cortex. Cortisol is one of the most important hormones in the human body, playing essential roles in virtually every organ system. It regulates carbohydrate, protein, and lipid metabolism; modulates the immune response and inflammatory processes; maintains cardiovascular stability and blood pressure; influences central nervous system function and mood; and is critical for the body's response to physiological stress including illness, injury, and surgery.
The Panpharma formulation is presented as a powder and solvent for solution for injection or infusion. The powder contains 100 mg of hydrocortisone (as the sodium succinate salt), which must be reconstituted with the accompanying solvent before use. Once dissolved, the solution can be administered by intravenous (IV) injection as a bolus, by slow IV infusion diluted in compatible intravenous fluids, or by intramuscular (IM) injection. The IV route is generally preferred in emergency situations because it provides the fastest onset of systemic drug levels, with peak plasma concentrations achieved within minutes of injection.
Hydrocortisone is unique among corticosteroids in that it provides both significant glucocorticoid activity (anti-inflammatory and immunosuppressive effects) and mineralocorticoid activity (regulation of sodium and potassium balance, blood volume, and blood pressure). This dual action makes it the corticosteroid of choice for replacement therapy in primary adrenal insufficiency (Addison's disease), where both glucocorticoid and mineralocorticoid functions of the adrenal gland are impaired. Other synthetic corticosteroids such as prednisolone, dexamethasone, and methylprednisolone have stronger glucocorticoid potency but substantially less mineralocorticoid activity.
The clinical indications for injectable Hydrocortisone Panpharma include a range of acute and emergency conditions:
- Acute adrenal insufficiency (adrenal crisis): This is a life-threatening emergency in which the body cannot produce sufficient cortisol. It may occur in patients with known adrenal insufficiency (Addison's disease or secondary adrenal insufficiency) who experience physiological stress such as infection, surgery, or trauma without adequate glucocorticoid dose adjustment. Symptoms include severe hypotension, hyponatremia, hyperkalemia, hypoglycemia, and circulatory collapse. Intravenous hydrocortisone 100 mg as an immediate bolus followed by continuous infusion or repeated doses is the standard first-line treatment recommended by the Endocrine Society guidelines.
- Severe allergic reactions and anaphylaxis: While epinephrine (adrenaline) is the first-line treatment for anaphylaxis, hydrocortisone is administered as an adjunctive therapy to reduce the risk of protracted or biphasic anaphylactic reactions. It helps suppress the underlying inflammatory immune response and may prevent late-phase symptoms that can occur 4 to 12 hours after initial presentation.
- Acute severe asthma (status asthmaticus): Injectable hydrocortisone is used when patients with acute asthma cannot take oral corticosteroids due to vomiting, impaired consciousness, or extreme breathlessness. International guidelines including GINA (Global Initiative for Asthma) recommend systemic corticosteroids as early as possible in acute severe asthma exacerbations.
- Shock: Hydrocortisone may be used in the management of septic shock, particularly when patients demonstrate inadequate hemodynamic response to fluid resuscitation and vasopressor therapy. The Surviving Sepsis Campaign guidelines suggest intravenous hydrocortisone (200 mg per day) for adults with septic shock who remain hemodynamically unstable despite adequate fluid and vasopressor therapy.
- Other acute inflammatory conditions: Injectable hydrocortisone may be used for severe inflammatory conditions such as acute exacerbations of inflammatory bowel disease, cerebral edema, transplant rejection, and other situations requiring rapid suppression of the immune response when oral administration is not feasible.
Hydrocortisone is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its fundamental importance in global healthcare. It has been in clinical use for over seven decades since its first synthesis in the 1950s, and its pharmacological properties, therapeutic applications, and safety profile are among the most thoroughly characterized of any medication in medicine.
Unlike other corticosteroids such as dexamethasone or prednisolone, hydrocortisone closely mimics the body's natural cortisol. Its combined glucocorticoid and mineralocorticoid activity, relatively short duration of action (allowing for physiological dosing patterns), and well-established safety profile make it the gold standard for adrenal replacement therapy. The Endocrine Society Clinical Practice Guidelines specifically recommend hydrocortisone as the first-choice glucocorticoid for patients with primary adrenal insufficiency.
What Should You Know Before Taking Hydrocortisone Panpharma?
Contraindications
The only absolute contraindication to hydrocortisone use is hypersensitivity to hydrocortisone sodium succinate or any of the excipients in the formulation. However, in true life-threatening emergencies such as anaphylaxis or adrenal crisis, there are no absolute contraindications to administration, as the immediate risk of death from the untreated condition far outweighs any potential risk from the drug.
For non-emergency use, hydrocortisone should not be used in patients with systemic fungal infections (such as systemic candidiasis or aspergillosis), as corticosteroids suppress immune function and may worsen these infections. This contraindication does not apply to patients receiving hydrocortisone as replacement therapy for adrenal insufficiency, where the dose simply replaces normal physiological cortisol levels rather than producing pharmacological immunosuppression.
Administration of live or live-attenuated vaccines is generally contraindicated in patients receiving immunosuppressive doses of corticosteroids, as the impaired immune response may lead to inadequate antibody formation and potentially allow the vaccine organism to cause infection. Killed or inactivated vaccines may be administered, although the immune response may be diminished.
Warnings and Precautions
Patients who have received hydrocortisone for more than a few days should never stop treatment suddenly. Abrupt withdrawal can precipitate acute adrenal insufficiency (adrenal crisis), which may be fatal. The dose must be reduced gradually under medical supervision to allow the hypothalamic-pituitary-adrenal (HPA) axis to recover. This risk applies to all routes of systemic corticosteroid administration.
Before starting treatment with Hydrocortisone Panpharma (in non-emergency situations), discuss the following conditions with your healthcare provider:
- Active or latent infections: Corticosteroids suppress the immune system and can mask signs and symptoms of infection, potentially allowing infections to worsen without obvious clinical signs. Patients with active tuberculosis should not receive corticosteroids unless they are concurrently receiving appropriate anti-tuberculosis chemotherapy. Latent tuberculosis may be reactivated, and patients with a positive tuberculin test should be closely monitored.
- Diabetes mellitus: Hydrocortisone increases blood glucose levels through its glucocorticoid effects on carbohydrate metabolism (gluconeogenesis, reduced peripheral glucose uptake). Patients with diabetes may require dose adjustments of their insulin or oral hypoglycemic agents. Blood glucose monitoring should be intensified during corticosteroid therapy.
- Peptic ulcer disease: Corticosteroids may increase the risk of gastrointestinal perforation and bleeding, particularly when used concomitantly with nonsteroidal anti-inflammatory drugs (NSAIDs). Patients with a history of peptic ulcer disease should be monitored closely, and gastroprotective therapy may be considered.
- Osteoporosis: Prolonged corticosteroid use is one of the most common causes of secondary osteoporosis. Patients at increased risk of osteoporosis (postmenopausal women, elderly patients, those with a family history) should have bone density assessed and may require prophylactic measures including calcium and vitamin D supplementation and, in some cases, bisphosphonate therapy.
- Psychiatric effects: Corticosteroids can cause a range of psychiatric disturbances including euphoria, insomnia, mood swings, personality changes, severe depression, and frank psychosis. These effects may occur at any dose but are more common with higher doses. Patients with a history of psychiatric illness should be closely monitored.
- Cardiovascular disease: Hydrocortisone can cause fluid retention and hypertension through its mineralocorticoid effects. Patients with congestive heart failure, hypertension, or renal insufficiency should be carefully monitored. Serum electrolytes (particularly sodium and potassium) should be checked regularly.
- Ocular effects: Prolonged corticosteroid use may lead to posterior subcapsular cataracts, increased intraocular pressure, and glaucoma. Regular ophthalmological examination is recommended for patients on long-term therapy.
Pregnancy and Breastfeeding
Hydrocortisone may be used during pregnancy when the potential benefits outweigh the risks, and it is essential in pregnant women with adrenal insufficiency who require continued replacement therapy. Hydrocortisone crosses the placenta but is largely inactivated by placental 11-beta-hydroxysteroid dehydrogenase type 2 (11β-HSD2), an enzyme that converts cortisol to the biologically inactive cortisone. This provides partial protection to the fetus from excessive glucocorticoid exposure. Among the systemic corticosteroids, hydrocortisone is considered the preferred choice during pregnancy precisely because of this placental metabolism, which results in lower fetal exposure compared to dexamethasone or betamethasone (which are not significantly metabolized by 11β-HSD2).
Prolonged or high-dose corticosteroid therapy during pregnancy may theoretically be associated with intrauterine growth restriction and neonatal adrenal suppression, although the clinical significance varies with the dose, duration, and timing of exposure. The benefit of treating an acute medical emergency or maintaining adequate adrenal replacement in the mother generally far outweighs these theoretical risks. Neonates born to mothers receiving significant doses of hydrocortisone during pregnancy should be observed for signs of adrenal insufficiency.
Hydrocortisone is excreted in breast milk. At physiological replacement doses, the amount transferred to the infant is generally considered too small to cause adverse effects. The British National Formulary (BNF) states that prednisolone and hydrocortisone are the preferred choices in breastfeeding mothers because infant exposure is minimal. Mothers receiving higher pharmacological doses should discuss the risks and benefits of breastfeeding with their healthcare provider.
Children
Hydrocortisone may be used in children for appropriate indications, including congenital adrenal hyperplasia, acute adrenal crisis, severe asthma, and severe allergic reactions. However, children are particularly susceptible to the growth-suppressing effects of systemic corticosteroids. Prolonged therapy should be accompanied by regular monitoring of height and growth velocity. The lowest effective dose should be used, and treatment duration should be kept as short as clinically feasible. Growth suppression is generally reversible upon discontinuation of therapy if the treatment period has not been excessively prolonged.
How Does Hydrocortisone Panpharma Interact with Other Drugs?
Hydrocortisone is metabolized primarily in the liver, predominantly by the cytochrome P450 enzyme CYP3A4, and is also a substrate for P-glycoprotein. Unlike monoclonal antibodies, hydrocortisone has a broad pharmacokinetic interaction profile, and concomitant medications can significantly affect its plasma levels, efficacy, and safety. Conversely, hydrocortisone itself can alter the metabolism, efficacy, or toxicity of numerous other drugs through both pharmacokinetic and pharmacodynamic mechanisms.
The following table summarizes the most clinically significant drug interactions with hydrocortisone:
| Drug / Drug Class | Interaction | Clinical Significance |
|---|---|---|
| NSAIDs (ibuprofen, naproxen, aspirin) | Increased risk of gastrointestinal ulceration and bleeding | Major – avoid concurrent use if possible; if necessary, consider gastroprotection with a proton pump inhibitor |
| Rifampicin | Potent CYP3A4 inducer; markedly increases hydrocortisone clearance, reducing plasma levels by up to 50% | Major – hydrocortisone dose may need to be doubled or tripled during concurrent rifampicin therapy |
| Phenytoin, carbamazepine, barbiturates | Hepatic enzyme inducers that accelerate corticosteroid metabolism | Major – reduced corticosteroid efficacy; dose adjustment may be required |
| Ketoconazole, itraconazole | CYP3A4 inhibitors; decrease hydrocortisone clearance, increasing plasma levels | Moderate – may enhance corticosteroid effects and toxicity; monitor for Cushingoid symptoms |
| Ritonavir and other HIV protease inhibitors | Potent CYP3A4 inhibitors; significantly increase hydrocortisone exposure | Major – co-administration has led to iatrogenic Cushing syndrome and adrenal suppression |
| Oral anticoagulants (warfarin) | Corticosteroids may enhance or diminish anticoagulant effect unpredictably | Moderate – monitor INR closely when initiating or changing corticosteroid dose |
| Antidiabetic agents (insulin, metformin, sulfonylureas) | Hydrocortisone increases blood glucose via gluconeogenesis and insulin resistance | Major – monitor blood glucose frequently; antidiabetic dose increases may be necessary |
| Diuretics (thiazides, loop diuretics) | Additive potassium loss leading to hypokalemia | Moderate – monitor serum potassium; consider potassium supplementation |
| Cardiac glycosides (digoxin) | Hypokalemia from corticosteroids increases risk of digoxin toxicity | Moderate – monitor potassium levels and signs of digoxin toxicity |
| Live vaccines (MMR, varicella, BCG, oral polio) | Immunosuppressive doses of corticosteroids may impair vaccine response and risk disseminated vaccine infection | Major – live vaccines are contraindicated during immunosuppressive corticosteroid therapy |
Additionally, certain herbal products may affect hydrocortisone metabolism. St. John's Wort (Hypericum perforatum) is a CYP3A4 inducer that may reduce corticosteroid plasma levels. Liquorice (glycyrrhizin) inhibits 11-beta-hydroxysteroid dehydrogenase type 2, the enzyme that inactivates cortisol, thereby potentiating the mineralocorticoid effects of hydrocortisone and increasing the risk of hypokalemia, hypertension, and edema. Patients should be advised to inform their healthcare provider about all herbal supplements and over-the-counter products they are using.
In patients with adrenal insufficiency receiving replacement-dose hydrocortisone (physiological doses of 15–25 mg/day in divided oral doses or equivalent parenteral doses), the interaction profile is generally less clinically significant than in patients receiving supraphysiological (anti-inflammatory or immunosuppressive) doses. However, enzyme-inducing drugs remain important because they can reduce replacement hydrocortisone levels below the threshold needed to prevent adrenal crisis.
Always carry an up-to-date medication list and inform every healthcare provider (including dentists and pharmacists) that you are taking or have recently taken hydrocortisone. This is especially important before any surgical procedure, dental work, or during intercurrent illness. If you have adrenal insufficiency, always wear a medical alert bracelet or carry a steroid alert card.
What Is the Correct Dosage of Hydrocortisone Panpharma?
The dosage of Hydrocortisone Panpharma varies widely depending on the clinical indication, severity of the condition, patient age and weight, and individual response. The 100 mg vial of powder must be reconstituted with the provided solvent before administration. Once reconstituted, the solution may be given by intravenous (IV) bolus injection, slow IV infusion (diluted in 0.9% sodium chloride or 5% glucose), or intramuscular (IM) injection. The IV route provides the fastest onset and is preferred in emergency situations.
Adults
| Indication | Initial Dose | Maintenance / Follow-up | Notes |
|---|---|---|---|
| Adrenal crisis | 100 mg IV bolus immediately | 200 mg/day continuous IV infusion or 50 mg IV every 6–8 hours | Taper to oral replacement as clinical condition improves; concurrent IV saline for volume resuscitation |
| Severe allergic reaction / Anaphylaxis | 100–500 mg IV or IM | Repeat every 6–8 hours as needed for 24–48 hours | Adjunctive to epinephrine (adrenaline); not a substitute for epinephrine as first-line treatment |
| Acute severe asthma | 100 mg IV every 6–8 hours | Convert to oral prednisolone when patient can swallow | Alternative to IV methylprednisolone; switch to oral corticosteroid as soon as feasible |
| Septic shock | 50 mg IV every 6 hours (200 mg/day) | Continue until vasopressors are no longer required, then taper | Per Surviving Sepsis Campaign guidelines; for patients refractory to fluids and vasopressors |
| Surgical stress coverage (known adrenal insufficiency) | 25–100 mg IV at induction of anesthesia | 25–50 mg IV every 8 hours for 24–72 hours, then resume oral dose | Dose depends on surgical severity (minor, moderate, or major procedure) |
For conditions not listed above, typical adult doses of injectable hydrocortisone range from 100 to 500 mg depending on the severity of the condition, administered IV or IM. The dose may be repeated at intervals of 2, 4, or 6 hours as clinically indicated. High-dose therapy should be continued only until the patient's condition has stabilized, at which point the dose should be reduced gradually.
Children
Pediatric dosing of injectable hydrocortisone is generally weight-based. For adrenal crisis in children, the Endocrine Society recommends an initial bolus of 50 mg/m² body surface area (BSA) or approximately 25 mg for infants, 50 mg for children aged 1–5 years, and 100 mg for older children and adolescents, given as an IV or IM injection. This is followed by 50–100 mg/m²/day in divided doses or as a continuous infusion until the crisis resolves and oral medication can be resumed.
For other indications in children, typical doses range from 1 to 5 mg/kg/day (or 30–150 mg/m²/day) in divided doses every 6 to 8 hours. The exact dose should be individualized according to the severity of the condition and the child's response. The lowest effective dose should be used to minimize the risk of growth suppression and other adverse effects associated with prolonged corticosteroid therapy in pediatric patients.
Elderly Patients
No specific dose adjustment is required solely on the basis of age. However, elderly patients may be more susceptible to the adverse effects of corticosteroids, including osteoporosis, diabetes, hypertension, susceptibility to infections, and skin thinning. Lower doses and shorter durations of therapy should be used where possible, and careful monitoring of blood glucose, blood pressure, bone density, and electrolytes is recommended. Elderly patients with adrenal insufficiency should receive the same emergency doses for adrenal crisis as younger adults.
Missed Dose
Hydrocortisone Panpharma is typically administered in acute or emergency settings by healthcare professionals, so missed doses are uncommon. For patients with adrenal insufficiency who use emergency injection kits at home, if a dose of their regular oral hydrocortisone is missed, it should be taken as soon as remembered. If it is close to the time of the next dose, the missed dose should be skipped and the regular schedule resumed. A double dose should never be taken to compensate. Patients should contact their healthcare provider if they are uncertain about what to do.
Overdose
Acute overdose of hydrocortisone is unlikely to cause immediate life-threatening toxicity. There is no specific antidote. A single large dose is generally well tolerated. Chronic overdosage or prolonged administration of supraphysiological doses produces the clinical features of Cushing syndrome: central obesity, moon face, striae, hypertension, hyperglycemia, muscle weakness, osteoporosis, and increased susceptibility to infections. Treatment of chronic overdosage involves gradual dose reduction under medical supervision. Abrupt withdrawal must be avoided to prevent adrenal crisis.
Patients with known adrenal insufficiency must increase their hydrocortisone dose during physiological stress (intercurrent illness, surgery, trauma). For minor illness with fever, the oral dose is typically doubled or tripled. For vomiting or inability to take oral medication, intramuscular hydrocortisone 100 mg should be administered immediately. Patients should carry an emergency injection kit and a steroid emergency card at all times. Failure to increase the dose during stress can precipitate a life-threatening adrenal crisis.
What Are the Side Effects of Hydrocortisone Panpharma?
The side effect profile of hydrocortisone depends critically on the dose, duration, and route of administration. At physiological replacement doses (15–25 mg/day orally or equivalent), hydrocortisone simply replaces what the body should naturally produce, and significant side effects are uncommon. Short-term high-dose therapy for acute emergencies (lasting days) is generally well tolerated, with the main effects being transient hyperglycemia and fluid retention. It is prolonged therapy at supraphysiological doses that carries the greatest risk of clinically significant adverse effects.
The following frequency categories are based on international guidelines and published literature for systemic corticosteroid therapy:
Very Common (affects more than 1 in 10 patients)
Primarily with prolonged supraphysiological doses
- Hyperglycemia (elevated blood sugar)
- Increased appetite and weight gain
- Insomnia and sleep disturbances
- Mood changes (euphoria, irritability)
- Fluid retention and peripheral edema
- Adrenal suppression (with chronic use)
Common (affects 1 in 10 to 1 in 100 patients)
May occur with short-term or moderate-dose use
- Increased blood pressure (hypertension)
- Hypokalemia (low potassium)
- Muscle weakness (proximal myopathy)
- Skin thinning and easy bruising
- Impaired wound healing
- Dyspepsia and gastrointestinal discomfort
- Increased susceptibility to infections
- Redistribution of body fat (truncal obesity, moon face)
Uncommon (affects 1 in 100 to 1 in 1,000 patients)
Primarily associated with long-term therapy
- Osteoporosis and pathological fractures
- Avascular necrosis of bone (particularly femoral head)
- Posterior subcapsular cataracts
- Glaucoma or increased intraocular pressure
- Peptic ulceration (especially with concurrent NSAID use)
- Pancreatitis
- Psychosis or severe depression
- Growth retardation in children
Rare (affects fewer than 1 in 1,000 patients)
Reported in post-marketing surveillance
- Anaphylaxis or severe hypersensitivity to the formulation
- Tendon rupture
- Seizures (especially at very high doses)
- Pseudotumor cerebri (benign intracranial hypertension)
- Kaposi sarcoma (reactivation with immunosuppression)
- Pheochromocytoma crisis (very rare, reported with high-dose IV corticosteroids)
It is important to distinguish between the effects of short-term emergency use and those of prolonged therapy. A single dose or short course (1–3 days) of injectable hydrocortisone for an emergency such as anaphylaxis, adrenal crisis, or acute asthma carries a very low risk of the chronic adverse effects listed above. The most commonly observed effects with short-term use are transient hyperglycemia, fluid retention, mild blood pressure elevation, and sleep disturbance. These typically resolve rapidly once treatment is discontinued.
Local effects at the injection site may include pain, redness, or sterile abscess formation, particularly with intramuscular administration. Perineal pruritus (itching in the genital area) has been reported with intravenous administration, typically when the injection is given too rapidly. This effect is transient and resolves spontaneously.
If you experience any side effects that concern you, whether listed here or not, contact your healthcare provider. For patients with adrenal insufficiency on long-term replacement therapy, regular medical follow-up is essential to monitor for complications and optimize dosing.
Contact emergency services or go to the nearest emergency department if you experience signs of a serious allergic reaction (difficulty breathing, swelling of face/tongue/throat, severe skin rash), signs of acute adrenal crisis (severe weakness, dizziness, confusion, loss of consciousness), or symptoms of severe infection (high fever, rigors, altered mental status) while taking corticosteroids.
How Should You Store Hydrocortisone Panpharma?
Proper storage of Hydrocortisone Panpharma is essential to maintain the stability and efficacy of the medication. The unopened vial containing the powder should be stored at a temperature not exceeding 25°C (77°F). Keep the vial in the original carton to protect it from light, as exposure to light can degrade the hydrocortisone sodium succinate over time. The product must not be frozen at any point during storage.
Once the powder has been reconstituted with the provided solvent, the resulting solution should ideally be used immediately. Chemical and physical in-use stability has been demonstrated for up to 24 hours at 2–8°C (refrigerator temperature). From a microbiological perspective, unless the reconstitution has been carried out under validated aseptic conditions, the product should be used immediately to minimize the risk of microbial contamination. Any unused solution remaining after 24 hours should be discarded.
For patients with adrenal insufficiency who carry emergency hydrocortisone injection kits, it is important to check the expiration date regularly and replace the kit before it expires. The kit should be stored in an accessible location and protected from extreme temperatures. When traveling, avoid leaving the medication in direct sunlight or in a hot vehicle. Some patients find it helpful to set calendar reminders to check and replace their emergency supplies.
As with all medications, keep Hydrocortisone Panpharma out of the sight and reach of children. Do not use the medication if the reconstituted solution is cloudy, discolored, or contains visible particles. Do not dispose of medications via wastewater or household waste. Ask your pharmacist about appropriate disposal methods in accordance with local environmental regulations.
What Does Hydrocortisone Panpharma Contain?
The active substance in Hydrocortisone Panpharma is hydrocortisone, present in the form of hydrocortisone sodium succinate. Each vial contains the equivalent of 100 mg of hydrocortisone. Hydrocortisone sodium succinate is a water-soluble ester of hydrocortisone that enables rapid dissolution for parenteral administration. Following injection, the sodium succinate ester is rapidly hydrolyzed by esterases in the blood and tissues to release free hydrocortisone, the pharmacologically active form.
The powder vial also contains buffer excipients, typically sodium dihydrogen phosphate dihydrate and disodium phosphate dihydrate, which maintain the pH of the reconstituted solution within an appropriate range for injection (approximately pH 7.0–8.0). These phosphate buffers ensure stability of the hydrocortisone sodium succinate during storage and upon reconstitution.
The accompanying solvent vial contains water for injections (aqua ad injectionem), a sterile, pyrogen-free grade of water specifically manufactured for parenteral pharmaceutical preparations. This solvent is used to dissolve the powder immediately before administration.
The reconstituted solution is clear and colorless to slightly yellow. The solution may be further diluted with 0.9% sodium chloride solution (normal saline) or 5% glucose (dextrose) solution for administration as an intravenous infusion. Compatibility with other intravenous solutions or admixtures should be confirmed before use, as hydrocortisone sodium succinate may be incompatible with certain drugs when mixed in the same infusion bag or syringe.
Hydrocortisone Panpharma does not contain preservatives, latex, or gluten. Patients with known sensitivities to any of the excipients should inform their healthcare provider before administration.
Frequently Asked Questions About Hydrocortisone Panpharma
Hydrocortisone Panpharma is an injectable corticosteroid used for emergency treatment of acute adrenal insufficiency (adrenal crisis), severe allergic reactions including anaphylaxis, acute severe asthma, septic shock, and other conditions requiring rapid systemic corticosteroid therapy. It provides the same cortisol hormone that the adrenal glands produce naturally and is listed on the WHO Model List of Essential Medicines.
When administered intravenously, hydrocortisone reaches peak plasma levels within minutes. However, the clinical effects depend on the mechanism of action: genomic effects (anti-inflammatory gene regulation) take several hours to become fully apparent, while some non-genomic effects (membrane stabilization, rapid hemodynamic support) may occur within 30 to 60 minutes. For adrenal crisis, clinical improvement in blood pressure and symptoms is typically seen within 1 to 2 hours of IV administration.
Patients with adrenal insufficiency may be trained by their healthcare team to self-administer intramuscular (IM) hydrocortisone injections in emergency situations, such as during adrenal crisis when oral medication cannot be taken due to vomiting. Emergency hydrocortisone injection kits are prescribed for this purpose. Patients and their family members should receive proper training on reconstitution, injection technique, and when to use the emergency kit. After self-injection, patients should still seek immediate medical attention.
Both are corticosteroids, but they differ in potency, duration of action, and mineralocorticoid activity. Hydrocortisone has a relatively short duration of action (8–12 hours biological half-life), moderate anti-inflammatory potency, and significant mineralocorticoid activity (affecting sodium/potassium balance). Dexamethasone is approximately 25–30 times more potent as an anti-inflammatory agent, has a much longer duration of action (36–54 hours), and has virtually no mineralocorticoid activity. Hydrocortisone is preferred for adrenal replacement because it mimics natural cortisol, while dexamethasone is often used when potent, long-lasting anti-inflammatory effects are needed.
No, they are closely related but distinct. Hydrocortisone is the pharmaceutical name for cortisol, the active glucocorticoid hormone produced by the adrenal glands. Cortisone is the inactive precursor that must be converted to cortisol (hydrocortisone) by the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 in the liver and other tissues before it becomes biologically active. Because hydrocortisone is already in its active form, it provides more predictable and reliable therapeutic effects, which is why it is the preferred agent for most clinical indications.
If you have adrenal insufficiency and develop a febrile illness, you should follow sick day rules: double or triple your usual oral hydrocortisone dose for the duration of the illness. If you are vomiting and cannot keep oral medication down, you should administer intramuscular hydrocortisone from your emergency kit (typically 100 mg) and contact your healthcare provider or go to the nearest emergency department immediately. Do not wait to see if you improve. Always carry your emergency injection kit, steroid alert card, and a written emergency management plan.
References
- Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(2):364–389. doi:10.1210/jc.2015-1710
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- European Medicines Agency. Hydrocortisone: Summary of Product Characteristics. EMA; 2024.
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press; 2025. Hydrocortisone monograph.
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47(11):1181–1247. doi:10.1007/s00134-021-06506-y
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention (2024 Update). Fontana, WI: GINA; 2024.
- Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal insufficiency. Lancet. 2021;397(10274):613–629. doi:10.1016/S0140-6736(21)00136-7
- Resuscitation Council UK. Emergency Treatment of Anaphylactic Reactions: Guidelines for Healthcare Providers. 2021 Update.
- Prete A, Taylor AE, Bancos I, et al. Prevention of Adrenal Crisis: Cortisol Responses to Major Stress Compared to Stress Dose Hydrocortisone Delivery. J Clin Endocrinol Metab. 2020;105(7):dgaa133. doi:10.1210/clinem/dgaa133
- Paragliola RM, Papi G, Pontecorvi A, Corsello SM. Treatment with Synthetic Glucocorticoids and the Hypothalamus-Pituitary-Adrenal Axis. Int J Mol Sci. 2017;18(10):2201. doi:10.3390/ijms18102201
Editorial Team
This article was written and reviewed by iMedic's medical editorial team, consisting of licensed physicians and pharmacists with expertise in endocrinology, emergency medicine, and clinical pharmacology.
Medical Writer
iMedic Medical Editorial Team – Specialists in endocrinology and clinical pharmacology with experience in corticosteroid therapy and adrenal disorders
Medical Reviewer
iMedic Medical Review Board – Independent panel of medical specialists who review all content according to international guidelines (Endocrine Society, WHO, EMA, BNF)
Pharmacology Review
Clinical pharmacologists with expertise in drug interactions, pharmacokinetics, and evidence-based medicine
Accessibility Review
WCAG 2.2 AAA compliance verified – Content tested with screen readers, keyboard navigation, and assistive technology
Published: | Last Reviewed: | Next Review Due: